To evaluate the efficacy of MIR155HG in predicting cancer patient response to checkpoint inhibitor, we used the TIMER database to analyze the relevance of MIR155HG and the currently available blocking molecules with superior therapeutic effects PD‐1, PD‐L1, CTLA4, LAG3, TIM3. The gene discussed is CD274; the disease is cancer.